Rinvoq (upadacitinib) Letter of Medical Necessity
Rinvoq (upadacitinib) carries a JAK class boxed warning that drives strict prior authorization criteria. LMNs must explicitly address age, cardiovascular risk, malignancy history, and prior TNF failure.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● atopic dermatitis
- ● ulcerative colitis
- ● Crohn's disease
Why Rinvoq Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Black box warning age/CV risk criteria not met
- 2. TNF inhibitor not tried first
- 3. Lab monitoring not documented
- 4. Severity scoring missing
What to Include in a Rinvoq Letter of Medical Necessity
Document age, CV risk profile, smoking history, prior TNF inhibitor trial outcomes, baseline labs (CBC, LFTs, lipids), and the clinical rationale for an oral JAK inhibitor over injectable alternatives.
Key clinical evidence to cite:
- ✓ SELECT-COMPARE, SELECT-MONOTHERAPY, MEASURE UP trials
- ✓ U-ACHIEVE and U-ACCOMPLISH for UC
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines (post-Oral Surveillance update)
- 📖 AGA 2020 IBD Guidelines
Rinvoq Prior Authorization Criteria
Standard criteria across major US payers for Rinvoq. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Rinvoq
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Rinvoq Prior Authorization FAQ
Why was my Rinvoq prior authorization denied?
The most common denial reasons for Rinvoq are: Black box warning age/CV risk criteria not met; TNF inhibitor not tried first; Lab monitoring not documented; Severity scoring missing.
What should a Rinvoq Letter of Medical Necessity include?
Document age, CV risk profile, smoking history, prior TNF inhibitor trial outcomes, baseline labs (CBC, LFTs, lipids), and the clinical rationale for an oral JAK inhibitor over injectable alternatives.
Which payers cover Rinvoq?
Rinvoq is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, though formulary tier and prior authorization criteria vary.